| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 20 Jan 2026 | 13 Jan 2026 |
| Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/01/2026 inter alia to consider and approve Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and Nine Months ended December 31 2025 and to transact other business matters. Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on January 20, 2026. Senores Pharmaceuticals Limited has informed the Exchange regarding the results for quarter and nine months ended December 31, 2025 Senores Pharmaceuticals Limited has informed the Exchange regarding Corrigendum to the Media Release submitted with the Outcome of the Board Meeting dated January 20, 2026. (As Per BSE Announcement Dated on:20.01.2026) | ||
| Board Meeting | 7 Jan 2026 | 3 Jan 2026 |
| Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/01/2026 ,inter alia, to consider and approve proposals for raising funds by way of issue of convertible warrants on preferential basis to the promotors/promoter group including determination of issue price. Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on January 07, 2026 (As Per BSE Announcement Dated on:07.01.2026) | ||
| Board Meeting | 15 Dec 2025 | 15 Dec 2025 |
| Senores Pharmaceuticals Limited has informed the Exchange regarding Acquisition | ||
| Board Meeting | 6 Nov 2025 | 29 Oct 2025 |
| Quarterly Results Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30,2025 and to transact other business matters . (As Per BSE Announcement Dated on 29.10.2025) Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of the Board Meeting held on November 06,2025 (As per BSE Announcement dated on: 06.11.2025) | ||
| Board Meeting | 23 Jul 2025 | 17 Jul 2025 |
| Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2025 inter alia to consider and approve Un-audited Standalone and Consolidated financial results of the Company for the quarter ended June 30 2025 and to transact other business matters. Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of the Board Meeting held on July 23, 2025. Senores Pharmaceuticals Limited has informed the Exchange regarding the Un-audited Standalone and Consolidated Financial Results for quarter ended on June 30, 2025. (As Per BSE Announcement Dated on :23.07.2025) | ||
| Board Meeting | 2 Jun 2025 | 2 Jun 2025 |
| Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on June 02, 2025. | ||
| Board Meeting | 15 May 2025 | 9 May 2025 |
| Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2025 inter alia to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31 2025; and to transact any other business matters. Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025. (As Per BSE Announcement Dated on :15.05.2025) | ||
The acquisition will be carried out in two tranches and has received approval from the management committee of the company’s board.
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Senores Pharmaceuticals shares closed 6% below their listing price, although they are still up 43% from the IPO price.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
